Biohaven Pharmaceutical (BHVN) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Biohaven Pharmaceutical (NYSE:BHVN) announced its quarterly earnings data on Tuesday. The company reported ($1.41) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.50) by $0.09, MarketWatch Earnings reports. During the same quarter last year, the firm posted ($2.32) earnings per share.

NYSE:BHVN opened at $60.10 on Wednesday. Biohaven Pharmaceutical has a twelve month low of $26.40 and a twelve month high of $64.83. The stock has a market cap of $2.53 billion, a price-to-earnings ratio of -9.77 and a beta of 0.60.

Several analysts recently commented on BHVN shares. Needham & Company LLC reiterated a “buy” rating and issued a $56.00 price objective (up previously from $48.00) on shares of Biohaven Pharmaceutical in a research note on Monday, March 4th. Cantor Fitzgerald reiterated a “buy” rating and issued a $75.00 price objective on shares of Biohaven Pharmaceutical in a research note on Friday, February 8th. ValuEngine upgraded shares of Biohaven Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Zacks Investment Research upgraded shares of Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research note on Tuesday, January 15th. Finally, Oppenheimer reiterated a “buy” rating on shares of Biohaven Pharmaceutical in a research note on Tuesday, March 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Biohaven Pharmaceutical has an average rating of “Buy” and an average price target of $69.19.

In other Biohaven Pharmaceutical news, CEO Vlad Coric sold 100,000 shares of the firm’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $50.09, for a total transaction of $5,009,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Declan Doogan sold 88,825 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $58.42, for a total transaction of $5,189,156.50. Following the transaction, the director now owns 373,913 shares of the company’s stock, valued at $21,843,997.46. The disclosure for this sale can be found here. Insiders have sold a total of 437,856 shares of company stock valued at $22,279,475 over the last 90 days. 23.90% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/05/08/biohaven-pharmaceutical-bhvn-posts-quarterly-earnings-results-beats-expectations-by-0-09-eps.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Featured Article: The role of implied volatility with call option volume

Earnings History for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.